Olyvia Carrasco, an active 18-year-old college student, found out she had autoimmune Type 1 diabetes only a few months ago after routine bloodwork at a doctor's appointment.
The diagnosis meant difficult changes to her lifestyle — diet, exercise, and monitoring her sugar levels — along with all the worries that come with a chronic illness. Then, the Albuquerque-based veterinary school student got the opportunity to receive a newly offered infusion treatment called Tzield (teplizumab) at CommonSpirit Mercy Hospital in Durango, Colorado.
The treatment can delay the onset of symptomatic autoimmune Type 1 diabetes for years. For Carrasco, 14 days of Tzield infusions have made her new condition far more manageable.
"I check [my blood sugar] here and there and obviously do not pretend I don't have it," Carrasco said. "But definitely I don't have to use insulin at all. The constant pokes after every meal — I don't have to worry about that."
How Tzield is Helping Patients at Risk for Type 1 Diabetes in Colorado
Thanks to Dr. Sarah Goodpastor and her team, Mercy Hospital is now the first hospital in Southwestern Colorado to offer infusions of Tzield, an FDA-approved therapy for people with Type 1 diabetes.
Dr. Goodpastor is a diabetologist at the CommonSpirit Mercy Diabetes and Metabolism Center who sees patients from across southwestern Colorado and New Mexico. With the support of colleagues across Mercy Hospital and CommonSpirit, she launched the hospital's Tzield infusion program earlier this year — just in time for Carrasco to become the program's first patient in August 2026.
The therapy has evolved along with a new understanding of Type 1 diabetes, which physicians and researchers now split into three stages. Tzield, which involves a single 14-day course of daily 30-minute infusions, is offered to patients with stage 2 Type 1 diabetes, when the disease isn't causing its telltale symptoms but is detectable through bloodwork and testing.
The treatment calms the immune system's attack on insulin-producing cells. It can delay the onset of stage 3 diabetes by an average of two to three years, giving patients more time without challenging symptoms and, critically, without daily insulin injections.
The therapy can be life-changing for patients. Because Mercy Hospital now offers Tzield, patients in rural Southwestern Colorado and New Mexico don't have to travel hundreds of miles to Denver, where Dr. Goodpastor was previously sending patients for infusions.
"I think it means everything when you're in a rural space," Dr. Goodpastor said. "My mission is to bring the types of treatments that people can get in an urban or academic center to a rural space, so that there isn't a discrepancy in care."
A Can-Do Attitude Brought Tzield to Mercy Hospital
Carrasco received the Tzield therapy at Mercy Hospital’s infusion center in August, just a few months after her diagnosis.
Her astute primary care provider in New Mexico suspected that Carrasco had autoimmune Type 1 diabetes rather than the more common Type 2 diabetes, since Carrasco is a young person with a lean physique. After checking Carrasco for antibodies to her insulin-producing cells, her physician sent her to the Mercy Diabetes Center, where Dr. Goodpastor was able to pinpoint her diabetes at stage 2 Type 1.
The diagnosis made Carrasco an ideal candidate for Tzield.
"She was interested in delaying the disease process," Dr. Goodpastor said. "She did not feel she could go to Denver. I felt like it was the right thing to do to make it happen here."
Because Tzield infusions happen every day for two weeks straight, Dr. Goodpastor had to convince Mercy Hospital's infusion center team not only to help her offer Tzield, but also to stay open on the weekends to deliver the treatment uninterrupted. Fortunately, her colleagues at the infusion center and the hospital's pharmacy team met her request with immediate enthusiasm.
"I think it's really just kind of a testament to the can-do attitude of everybody at Mercy that's out here in a rural community, that they were just like, 'We could bring this to a rural community. This is so cool. This is so neat. I totally want to be a part of this,’" Dr. Goodpastor said.
Carrasco had minor side effects like nausea and headaches from her infusions, and will continue with regular check-ups and lab work. But for now, she doesn't have to rely on insulin, and Tzield will let her continue her college studies with less worry.
"It's only a one-time thing," Carrasco said. "And it really does save you a lot of time, a lot of stress, and worry about just how you are as a person and your health. I just say just go for it."
Dr. Goodpastor said there are also financial benefits to a course of Tzield.
Even with insurance, the cost of insulin, pumps and monitors, and medical appointments can reach $20,000 a year for a person with Type 1 stage 3 diabetes. If a person's unmanaged stage 3 diabetes sends them into diabetic ketoacidosis, a trip to the ICU can cost tens of thousands of dollars.
With Tzield, patients can delay the disease's progression to this stage by at least a few years.
"This therapy offers our patient the profound benefit of additional years free from insulin dependence, a reduced disease burden, and the preservation of vital beta-cell function during a critical window of time," Dr. Goodpastor said. "This couldn't have been made possible without the work of the diabetes clinic team, our hospital pharmacy, and infusion center partners. Bringing innovations like this to fruition truly highlights the multidisciplinary collaboration and dedication required to provide truly patient-centered care."
The Importance of Diabetes Screening
A treatment like Tzield is only helpful when at-risk patients are identified early through antibody screening for Type 1 diabetes.
While screenings initially started with people whose relatives had Type 1 diabetes — and are extremely important for patients with family history of autoimmune disease, who may be at heightened risk — the process is now available and recommended for anyone.
"What's in the Type 1 diabetes screening guidelines from the American Diabetes Association, as of 2026, is to screen anyone with a relative with T1D and/or a personal or family history of any autoimmune disease at minimum,” Dr. Goodpastor said, “but with free screening programs, I recommend we follow our European colleagues and screen everyone.”
Without screenings, it can be difficult to even identify those at risk for the disease. Ninety percent of people diagnosed with Type 1 diabetes have no family history of the disease, leaving them unaware they may be at risk themselves, Dr. Goodpastor said. That number makes it important that everyone, regardless of family autoimmune disease history, be screened.
Screenings sound an early alarm and can catch Type 1 diabetes before significant symptoms appear. About 65% of people with new-onset stage 3 Type 1 diabetes dramatically present with an episode of diabetic ketoacidosis, which can be life-threatening, according to the Barbara Davis Center for Diabetes. Screening the general population helps cut that number to 5%, allowing patients and physicians to catch the disease before it starts causing serious symptoms, Dr. Goodpastor said.
Dr. Goodpastor recommended two free screening programs for anyone interested in evaluating their own risk for developing Type 1 diabetes and potentially catching it early: Autoimmunity Screening for Kids and the STOP T1D Screening Program. Both are academic offerings from the Barbara Davis Center; a patient’s results are confidential.
These screenings go beyond the typical A1C evaluations included in routine bloodwork; instead, they're looking for antibodies specific to the cells that produce insulin in a patient's blood. These antibodies can be present many years before the disease manifests as elevated blood sugar.
Dr. Goodpastor and her team can follow at-risk patients and monitor them for any change in blood sugar in coordination with their primary care provider.
"Even if people don't want to do Tzield, just by knowing whether or not they're at risk for Type 1 diabetes, they can reduce their risk of having a terrifying episode of life-threatening diabetic ketoacidosis and a $30,000 ICU bill," Dr. Goodpastor said.
Learn more about diabetes care, prevention and education, and find a diabetes care provider near you.